Immunotherapy plus chemotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, followed by radiation to the chest, for people with extensive-stage small cell lung cancer who have not been treated yet. The goal is to see if this approach can shrink the cancer and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have extensive-stage small cell lung cancer (cancer that has spread beyond the lung and nearby lymph nodes).
- You must not have had any prior chemotherapy or immunotherapy for this cancer.
- You need to be in generally good health (able to care for yourself and out of bed more than half the day).
- If you have had surgery or radiation for a previous cancer, that must have ended at least 6 months before your small cell lung cancer diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab), chemotherapy, and then radiation to the chest for people with extensive-stage small cell lung cancer who haven't had prior treatment. The goal is to see if this approach helps control the cancer longer.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Hear when a new ES-SCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.